Expression profile of SIRT2 in human melanoma and implications for sirtuin-based chemotherapy

Cell Cycle. 2017 Mar 19;16(6):574-577. doi: 10.1080/15384101.2017.1288323. Epub 2017 Feb 6.

Abstract

Melanoma is cancer of melanin-containing melanocyte cells. This neoplasm is one of the most deadly forms of skin cancer, and currently available therapeutic options are insufficient in significantly improve outcomes for many patients. Therefore, novel targets are required to effectively manage this neoplasm. Several sirtuins have previously been found to be upregulated in melanoma, so in this study, the expression profile of SIRT2 was determined. Employing a tissue microarray containing benign nevi, primary melanomas, and lymph node metastases, we have found that the tissue from lymph node metastases appears to have a significant upregulation of SIRT2 relative to primary tumors across the nuclear, cytoplasmic, and whole cell data. Additionally, SIRT2 staining was found to be higher in the nucleus of metastatic melanomas compared to cytoplasmic staining. As SIRT2 is considered to be a predominantly cytoplasmic protein, this is a novel and very interesting finding. This, combined with previous studies that show other sirtuins are increased in melanoma and involved in cellular proliferation and survival, leads to the suggestion that exploring pan-sirtuin inhibitors may be the best target for the next iteration of melanoma chemotherapeutics.

Keywords: Cellular localization; Chemotherapy; Melanoma; SIRT2; Sirtuins; Skin.

MeSH terms

  • Cell Line, Tumor
  • Gene Expression Profiling*
  • Gene Expression Regulation, Neoplastic*
  • Humans
  • Melanoma / drug therapy*
  • Melanoma / genetics*
  • Neoplasm Metastasis
  • Sirtuin 2 / metabolism*

Substances

  • Sirtuin 2